Holen Sie sich die Stockscreener-App
0.8016
5.15%
-0.0435
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SCYX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8451
Offen:
$0.866
24-Stunden-Volumen:
137.08K
Relative Volume:
0.73
Marktkapitalisierung:
$31.28M
Einnahmen:
$135.87M
Nettoeinkommen (Verlust:
$72.20M
KGV:
0.5645
EPS:
1.42
Netto-Cashflow:
$45.09M
1W Leistung:
-8.39%
1M Leistung:
-2.12%
6M Leistung:
-28.43%
1J Leistung:
-51.42%
1-Tages-Spanne:
$0.8016
$0.88
1-Wochen-Bereich:
$0.8016
$0.9212
52-Wochen-Spanne:
$0.66
$1.79
Scynexis Inc Stock (SCYX) Company Profile
Firmenname
Scynexis Inc
Sektor
Telefon
201-884-5485
Adresse
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Vergleichen Sie SCYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.8016 | 32.98M | 135.87M | 72.20M | 45.09M | 1.42 |
|
ZTS
Zoetis Inc
|
153.06 | 67.56B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.80 | 46.65B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.70 | 43.48B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.54 | 19.74B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.06 | 14.01B | 2.99B | 1.21B | 1.13B | 25.06 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-22 | Eingeleitet | Guggenheim | Buy |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Hochstufung | Needham | Hold → Buy |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-10 | Eingeleitet | ROTH Capital | Buy |
| 2017-05-09 | Herabstufung | Needham | Buy → Hold |
| 2017-03-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-07 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2016-08-17 | Eingeleitet | Guggenheim | Buy |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-08-09 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Eingeleitet | Brean Capital | Buy |
| 2015-12-29 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-06-10 | Eingeleitet | Needham | Buy |
| 2014-05-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2014-05-29 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Scynexis Inc Aktie (SCYX) Neueste Nachrichten
Key metrics from SCYNEXIS Inc.’s quarterly dataTreasury Yields & Real-Time Chart Pattern Alerts - Newser
Scynexis 2025 Q2 Earnings Significant Loss Reduction - AInvest
Is SCYNEXIS Inc. stock poised for growthCEO Change & Short-Term Trading Opportunity Alerts - Newser
Sector ETF performance correlation with SCYNEXIS Inc.2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Why SCYNEXIS Inc. stock attracts strong analyst attentionJuly 2025 Short Interest & AI Powered Market Entry Strategies - Newser
Can SCYNEXIS Inc. hit a new high this monthJuly 2025 WrapUp & Low Volatility Stock Suggestions - Newser
How high can SCYNEXIS Inc. stock goPrice Action & Growth Focused Investment Plans - Newser
What’s next for SCYNEXIS Inc. stock priceJuly 2025 Rallies & Safe Capital Allocation Plans - Newser
Scynexis: Q2 Earnings Snapshot - Stamford Advocate
SCYNEXIS Reports Improved Financials Amidst Strategic Developments - TipRanks
Will a bounce in SCYNEXIS Inc. offer an exitTrade Entry Report & Fast Entry High Yield Stock Tips - Newser
SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment - MSN
SCYNEXIS Inc. Earnings Report Breakdown: What Investors Should KnowMarket Movement Recap & Safe Entry Momentum Tips - Newser
Scynexis Inc earnings beat by $0.06, revenue topped estimates - Investing.com India
Scynexis reports Q2 EPS (14c), consensus (19c) - TipRanks
SCYNEXIS Doses First Patient in Phase 3 MARIO Study, $10M Milestone Payment Triggered Amid Ongoing Dispute with GSK - Quiver Quantitative
SCYNEXIS Restarts Key Phase 3 Trial but Faces Payment Dispute with Partner GSK over $30M Milestone - Stock Titan
SCYNEXIS Inc. stock trend forecastJuly 2025 Institutional & High Win Rate Trade Tips - Newser
Historical volatility pattern of SCYNEXIS Inc. visualizedQuarterly Trade Review & Capital Efficient Trade Techniques - Newser
Price momentum metrics for SCYNEXIS Inc. explainedWeekly Trade Recap & High Return Trade Opportunity Guides - Newser
SCYNEXIS Inc. stock retracement – recovery analysis2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - Newser
Can SCYNEXIS Inc. hit a new high this month [Weekly Trading Summary]Weekly Chart Analysis and Trade Guides - Newser
Using Python tools to backtest SCYNEXIS Inc. strategiesMarket Activity Report & Weekly Chart Analysis and Guides - Newser
Chartists See Breakout Potential in SCYNEXIS Inc.Low Risk Swing Trade Opportunities Identified - 선데이타임즈
Published on: 2025-08-11 23:14:27 - Newser
Technical analysis overview for SCYNEXIS Inc. stockFree Fundamental Winners With Safe Entry Plan - Newser
Reviewing CytoDyn (OTCMKTS:CYDY) & SCYNEXIS (NASDAQ:SCYX) - Defense World
What candlestick patterns are forming on SCYNEXIS Inc.Triple Digit Gain Opportunity Watchlist - Newser
Top chart patterns to watch in SCYNEXIS Inc.Secure Asset Flow and Trend Pattern Analysis - Newser
Real time scanner hits for SCYNEXIS Inc. explainedAI-Powered Stock Trend Movement Analysis - Newser
Applying big data sentiment scoring on SCYNEXIS Inc.Short-Term Upside Breakout Forecast System - Newser
Volatility clustering patterns for SCYNEXIS Inc.AI Short-Term Gain Forecast with Data - Newser
Finanzdaten der Scynexis Inc-Aktie (SCYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.29%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):